AURINIA PHARMACEUTICALS INC (AUPH) Stock News
NASDAQ:AUPH - Nasdaq - CA05156V1022 - Common Stock - Currency: USD
AUPH Latest News, Press Relases and Analysis
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
Tariff turmoil: What P&G, Pepsi and other companies are saying about tariffs
Tariff worries continue hanging over companies as they report their latest financial results and try to provide guidance on their path ahead. The tariff and trade picture continues shifting and that makes it difficult for companies and investors to make a reliable assessment of any impact to costs and sales. Seemingly few industries or companies are being spared from the uncertainty.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Mentions: MYNZ
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Aurinia to Participate in Jefferies London Healthcare Conference
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
Aurinia Announces Board Restructuring
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Aurinia Announces 2024 Annual General Meeting Results
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
Aurinia Provides Update on Proxy Statement
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
